Pancreatic Cancer Research

ResearcherShanghai University of Medicine and Health SciencesActive in the last 2 years

Zhenliang Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7651-0600; OpenAlex author ID A5009894408. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 3

  1. Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acscentsci.3c01440↗
  2. Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-0997↗
  3. Triptolide suppresses pancreatic cancer cell proliferation by inhibiting hedgehog signaling pathway activity. Last author DOI 10.1007/s11427-018-9477-3↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mingyao Liu · 2 shared papers, 2023–2024 · strength 0.34
  2. Yihua Chen · 2 shared papers, 2023–2024 · strength 0.34
  3. Chen Huang · 2 shared papers, 2023–2024 · strength 0.34
  4. Zhengfang Yi · 2 shared papers, 2023–2024 · strength 0.34
  5. Peng He · 1 shared paper, 2024 · strength 0.18
  6. Juanjuan Feng · 1 shared paper, 2019 · strength 0.10
  7. Lin Liang · 1 shared paper, 2019 · strength 0.10
  8. Xiufeng Pang · 1 shared paper, 2019 · strength 0.10
  9. Weiqiang Lü · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.